CRITICAL PATH INSTITUTE: Form 990, tax year 2015
View the entire original 990 at ProPublica ↗
- Organization
- CRITICAL PATH INSTITUTE (EIN 20-1991334)
- Tax period
- 2015-07-01 to 2016-06-30
- Filed
- 2017-02-09
- IRS object ID
- 201710409349300521
- Schema version
- 2015v3.0
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2017-02-09T15:26:28-06:00 | ReturnTs |
| Tax Period End | 2016-06-30 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 860683059 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | BEACHFLEISCHMAN PC | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1985 EAST RIVER ROAD SUITE 201 | AddressLine1Txt |
| City | TUCSON | CityNm |
| State Abbreviation | AZ | StateAbbreviationCd |
| ZIP | 85718 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2015-07-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 201991334 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | CRITICAL PATH INSTITUTE | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | CRIT | BusinessNameControlTxt |
| Phone | 5205473440 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1730 EAST RIVER ROAD NO 200 | AddressLine1Txt |
| City | TUCSON | CityNm |
| State Abbreviation | AZ | StateAbbreviationCd |
| ZIP | 857185898 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | STEVEN BROADBENT MBA | PersonNm |
| Person Title | COO | PersonTitleTxt |
| Phone | 5205473440 | PhoneNum |
| Signature | 2017-02-08 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | KAREN K MCCLOSKEY CPA | PreparerPersonNm |
| PTIN | P00099644 | PTIN |
| Phone | 5203214600 | PhoneNum |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2015 | TaxYr |
| Build TS | 2021-01-29 14:40:06Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | MARTHA BRUMFIELD PHD | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1730 EAST RIVER ROAD NO 200 | AddressLine1Txt |
| City | TUCSON | CityNm |
| State Abbreviation | AZ | StateAbbreviationCd |
| ZIP | 857185898 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $15,347,078 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.C-PATH.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 2004 | FormationYr |
| Legal Domicile State | AZ | LegalDomicileStateCd |
| Activity Or Mission | CREATE AND MANAGE INTERNATIONAL COLLABORATIONS TO RESOLVE PROBLEMS AND DEVELOP NOVEL TOOLS, ENABLING THE FASTER DEVELOPMENT OF SAFER MEDICAL PRODUCTS. | ActivityOrMissionDesc |
| Voting Members Governing Body | 14 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 13 | VotingMembersIndependentCnt |
| Total Employee | 64 | TotalEmployeeCnt |
| Total Volunteers | 14 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $10,269,810 | PYContributionsGrantsAmt |
| CY Contributions Grants | $10,197,464 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $3,715,780 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $5,069,034 | CYProgramServiceRevenueAmt |
| PY Investment Income | $13,987 | PYInvestmentIncomeAmt |
| CY Investment Income | $15,089 | CYInvestmentIncomeAmt |
| PY Other Revenue | $69,216 | PYOtherRevenueAmt |
| CY Other Revenue | $51,912 | CYOtherRevenueAmt |
| PY Total Revenue | $14,068,793 | PYTotalRevenueAmt |
| CY Total Revenue | $15,333,499 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $3,684,743 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $2,657,978 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $4,934,299 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $6,010,064 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $0 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $4,558,896 | PYOtherExpensesAmt |
| CY Other Expenses | $5,997,897 | CYOtherExpensesAmt |
| PY Total Expenses | $13,177,938 | PYTotalExpensesAmt |
| CY Total Expenses | $14,665,939 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $890,855 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $667,560 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $15,716,704 | TotalAssetsBOYAmt |
| Total Assets EOY | $18,234,620 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $10,932,273 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $12,782,629 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $4,784,431 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $5,451,991 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | THE CRITICAL PATH INSTITUTE IS A CATALYST IN THE DEVELOPMENT OF NEW APPROACHES THAT ADVANCE MEDICAL INNOVATION AND REGULATORY SCIENCE. THIS IS ACHIEVED BY LEADING TEAMS THAT SHARE DATA, KNOWLEDGE AND EXPERTISE RESULTING IN SOUND, CONSENSUS BASED SCIENCE. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $12,217,622 | ExpenseAmt |
| Grant | $2,657,978 | GrantAmt |
| Revenue | $5,069,034 | RevenueAmt |
| Desc | SEE SCHEDULE O | Desc |
| Total Program Service Expenses | $12,217,622 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Temp Or Permanent Endowments | 0 | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | 0 | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (1) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | 0 | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | 0 | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | 0 | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | Yes (1) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (1) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | 0 | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 37 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 64 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | 0 | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 14 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 13 | IndependentVotingMemberCnt |
| Family Or Business Rln | Yes (1) | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AZ | StatesWhereCopyOfReturnIsFldCd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | STEVE BROADBENT | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 5206478382 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1730 EAST RIVER ROAD SUITE 200 | AddressLine1Txt |
| City | TUCSON | CityNm |
| State Abbreviation | AZ | StateAbbreviationCd |
| ZIP | 857185898 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (23 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | OfficerOfficerInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|
| LYLE J BOOTMAN PHD SCD | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| D CRAIG BRATER MD | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| THE HONORABLE JAMES C GREENWOOD | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| MICHAEL KASSER MBA PHD | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| SHAUN A KIRKPATRICK MA | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| RICHARD T MYERS JR | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| CINDY PARSEGHIAN MBA | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| ALASTAIR JJ WOOD MB CHB | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| PETER BARTON HUTT LLB LLM | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| ALAN G LEVIN MS CPA | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| PAULA OLSIEWSKI PHD | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| JEFFREY E JACOB SM | |||||||
| DEPUTY CHAIR | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| M WAINWRIGHT FISHBURN JR | |||||||
| VICE CHAIRMAN | 1.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |
| TIMOTHY R FRANSON MD | |||||||
| CHAIRMAN OF THE BOARD FROM 6/16 | 1.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |
| PETER B CORR MD PHD | |||||||
| CHAIRMAN OF THE BOARD TIL 6/16 | 1.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |
| MARTHA A BRUMFIELD PHD | |||||||
| CHIEF EXECUTIVE OFFICER | 40.00 | Yes (X) | $296,522 | $0 | $30,054 | Yes (X) | |
| STEVEN T BROADBENT MBA | |||||||
| CHIEF OPERATING OFFICER & TREASURER | 40.00 | $187,269 | $0 | $26,290 | Yes (X) | ||
| ENRIQUE AVILES | |||||||
| SECRETARY | 40.00 | $157,130 | $0 | $22,255 | Yes (X) | ||
| LYNN D HUDSON PHD | |||||||
| CHIEF SCIENCE OFFICER | 40.00 | $191,637 | $0 | $18,114 | Yes (X) | ||
| JOHN-MICHAEL SAUER PHD | |||||||
| EXECUTIVE DIRECTOR PSTC | 40.00 | $179,842 | $0 | $26,538 | Yes (X) | ||
| STEPHEN J COONS PHD | |||||||
| EXECUTIVE DIRECTOR PROC | 40.00 | $175,956 | $0 | $20,673 | Yes (X) | ||
| DIANE STEPHENSON PHD | |||||||
| EXECUTIVE DIRECTOR CPP | 40.00 | $162,784 | $0 | $23,508 | Yes (X) | ||
| DEBRA HANNA PHD | |||||||
| EXECUTIVE DIRECTOR CPTR | 40.00 | $159,054 | $0 | $22,591 | Yes (X) | ||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $1,510,194 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $190,023 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 12 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/ForeignAddress/AddressLine1Txt | CityContractorAddress/ForeignAddress/CityNm | CountryContractorAddress/ForeignAddress/CountryCd | Foreign PostalContractorAddress/ForeignAddress/ForeignPostalCd | ServicesServicesDesc | CompensationCompensationAmt | Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd |
|---|---|---|---|---|---|---|---|---|---|
| ADELPHI VALUES | |||||||||
| ADELPHI MILL BOLLINGTON | CHESIRE | UK | SK105JB | RESEARCH | $689,270 | ||||
| PHARSIGHT CORPORATION | |||||||||
| SOFTWARE AND STATISTICAL MODEL | $506,072 | PO BOX 200854 | PITTSBURG | PA | 15251 | ||||
| HEALTH RESEARCH ASSOCIATES | |||||||||
| RESEARCH | $340,156 | 6505 216TH STREET SW SUITE 105 | MOUNTLAKE TERRACE | WA | 98043 | ||||
| EPHIBIAN | |||||||||
| SOFTWARE DEV, WEB AND INFO SECURITY | $240,494 | 3180 N SWAN ROAD | TUCSON | AZ | 85712 | ||||
| ANN ROBBINS LLC | |||||||||
| REGULATORY EXPERT CONSULTANT | $154,450 | 6430 SUN EALE LANE UNIT 301 | BRADENTON | FL | 34210 | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 10 | CntrctRcvdGreaterThan100KCnt |
| Government Grants | $3,200,284 | GovernmentGrantsAmt |
| All Other Contributions | $6,997,180 | AllOtherContributionsAmt |
| Total Contributions | $10,197,464 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt |
|---|---|---|---|
| RESEARCH SUPPORT FEES | 541700 | $4,912,824 | $4,912,824 |
| OTHER REVENUE | 900099 | $156,210 | $156,210 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $5,069,034 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $28,668 | TotalRevenueColumnAmt |
| Exclusion | $28,668 | ExclusionAmt |
Gross Rents GrossRentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $51,912 | RealAmt |
Less Rental Expenses LessRentalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $0 | RealAmt |
Rental Income Or Loss RentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $51,912 | RealAmt |
Net Rental Income Or Loss NetRentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $51,912 | TotalRevenueColumnAmt |
| Exclusion | $51,912 | ExclusionAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other | $13,579 | OtherAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other | -$13,579 | OtherAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$13,579 | TotalRevenueColumnAmt |
| Exclusion | -$13,579 | ExclusionAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $15,333,499 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $5,069,034 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $67,001 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part IX | Yes (X) | InfoInScheduleOPartIXInd |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,600,182 | TotalAmt |
| Program Services | $2,600,182 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $57,796 | TotalAmt |
| Program Services | $57,796 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $707,214 | TotalAmt |
| Program Services | $294,552 | ProgramServicesAmt |
| Management And General | $412,662 | ManagementAndGeneralAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,309,832 | TotalAmt |
| Program Services | $3,084,036 | ProgramServicesAmt |
| Management And General | $1,225,796 | ManagementAndGeneralAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $310,142 | TotalAmt |
| Program Services | $224,418 | ProgramServicesAmt |
| Management And General | $85,724 | ManagementAndGeneralAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $345,738 | TotalAmt |
| Program Services | $241,442 | ProgramServicesAmt |
| Management And General | $104,296 | ManagementAndGeneralAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $337,138 | TotalAmt |
| Program Services | $229,692 | ProgramServicesAmt |
| Management And General | $107,446 | ManagementAndGeneralAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $62,758 | TotalAmt |
| Program Services | $60,040 | ProgramServicesAmt |
| Management And General | $2,718 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $139,477 | TotalAmt |
| Program Services | $102,514 | ProgramServicesAmt |
| Management And General | $36,963 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $10,000 | TotalAmt |
| Management And General | $10,000 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,407,844 | TotalAmt |
| Program Services | $3,357,310 | ProgramServicesAmt |
| Management And General | $50,534 | ManagementAndGeneralAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $220,154 | TotalAmt |
| Program Services | $164,317 | ProgramServicesAmt |
| Management And General | $55,837 | ManagementAndGeneralAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $224,574 | TotalAmt |
| Program Services | $193,398 | ProgramServicesAmt |
| Management And General | $31,176 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $290,530 | TotalAmt |
| Program Services | $247,315 | ProgramServicesAmt |
| Management And General | $43,215 | ManagementAndGeneralAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $448,272 | TotalAmt |
| Program Services | $257,102 | ProgramServicesAmt |
| Management And General | $191,170 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $458,967 | TotalAmt |
| Program Services | $429,854 | ProgramServicesAmt |
| Management And General | $29,113 | ManagementAndGeneralAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $457,039 | TotalAmt |
| Program Services | $436,880 | ProgramServicesAmt |
| Management And General | $20,159 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $68,637 | TotalAmt |
| Program Services | $47,013 | ProgramServicesAmt |
| Management And General | $21,624 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $45,365 | TotalAmt |
| Program Services | $30,907 | ProgramServicesAmt |
| Management And General | $14,458 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (3 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt |
|---|---|---|---|
| BAD DEBT EXPENSE | $132,500 | $132,500 | |
| DUES AND SUBSCRIPTIONS | $21,844 | $18,511 | $3,333 |
| MISCELLANEOUS | $9,936 | $7,843 | $2,093 |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $14,665,939 | TotalAmt |
| Program Services | $12,217,622 | ProgramServicesAmt |
| Management And General | $2,448,317 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,758,599 | BOYAmt |
| EOY | $4,084,148 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,214,664 | BOYAmt |
| EOY | $8,406,753 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $403,661 | BOYAmt |
| EOY | $327,557 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $438,101 | BOYAmt |
| EOY | $1,023,373 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $37,395 | BOYAmt |
| EOY | $42,542 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $873,242 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $786,731 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $121,311 | BOYAmt |
| EOY | $86,511 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,727,502 | BOYAmt |
| EOY | $4,248,265 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $15,471 | BOYAmt |
| EOY | $15,471 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $15,716,704 | BOYAmt |
| EOY | $18,234,620 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,167,646 | BOYAmt |
| EOY | $632,632 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $9,764,627 | BOYAmt |
| EOY | $12,149,997 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $10,932,273 | BOYAmt |
| EOY | $12,782,629 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,784,431 | BOYAmt |
| EOY | $5,451,991 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,784,431 | BOYAmt |
| EOY | $5,451,991 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $15,716,704 | BOYAmt |
| EOY | $18,234,620 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | $667,560 | ReconcilationRevenueExpnssAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Separate Basis Fincl Stmt | Yes (X) | SeparateBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $7,998,908 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $5,915,630 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $5,370,782 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $10,269,811 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $10,197,464 | CurrentTaxYearAmt |
| Total | $39,752,595 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $7,998,908 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $5,915,630 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $5,370,782 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $10,269,811 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $10,197,464 | CurrentTaxYearAmt |
| Total | $39,752,595 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $12,673,465 | SubstantialContributorsTotAmt |
| Public Support Total170 | $27,079,130 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $22,660 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $21,279 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $70,230 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $82,059 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $80,580 | CurrentTaxYearAmt |
| Total | $276,808 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $20,745 | CurrentTaxYearMinus4YearsAmt |
| Total | $20,745 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $40,050,148 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $17,330,876 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.67610 | PublicSupportCY170Pct |
| Public Support PY170 | 0.79310 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
Total Direct Lobbying TotalDirectLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $11,731 | FilingOrganizationsTotalAmt |
Total Lobbying Expend TotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $11,731 | FilingOrganizationsTotalAmt |
Other Exempt Purpose Expend OtherExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $14,654,208 | FilingOrganizationsTotalAmt |
Total Exempt Purpose Expend TotalExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $14,665,939 | FilingOrganizationsTotalAmt |
Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $883,297 | FilingOrganizationsTotalAmt |
Grassroots Nontaxable GrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $220,824 | FilingOrganizationsTotalAmt |
Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $617,482 | CurrentYearMinus3Amt |
| Current Year Minus2 | $551,743 | CurrentYearMinus2Amt |
| Current Year Minus1 | $809,246 | CurrentYearMinus1Amt |
| Current Year | $883,297 | CurrentYearAmt |
| Total | $2,861,768 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Lobbying Ceiling | $4,292,652 | LobbyingCeilingAmt |
Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $60,071 | CurrentYearMinus3Amt |
| Current Year Minus2 | $60,221 | CurrentYearMinus2Amt |
| Current Year Minus1 | $67,262 | CurrentYearMinus1Amt |
| Current Year | $11,731 | CurrentYearAmt |
| Total | $199,285 | TotalAmt |
Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $154,371 | CurrentYearMinus3Amt |
| Current Year Minus2 | $137,936 | CurrentYearMinus2Amt |
| Current Year Minus1 | $202,312 | CurrentYearMinus1Amt |
| Current Year | $220,824 | CurrentYearAmt |
| Total | $715,443 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grassroots Ceiling | $1,073,165 | GrassrootsCeilingAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART II-A, LINE 1B | FormAndLineReferenceDesc |
| Explanation | C-PATH EXPENDS A MINOR AMOUNT OF TIME AND RESOURCES TO EDUCATE MEMBERS OF CONGRESS IN THE AREA OF DRUG DEVELOPMENT. | ExplanationTxt |
Schedule D IRS990ScheduleD
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $164,184 | OtherCostOrOtherBasisAmt |
| Depreciation | $140,425 | DepreciationAmt |
| Book Value | $23,759 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $237,326 | OtherCostOrOtherBasisAmt |
| Depreciation | $236,975 | DepreciationAmt |
| Book Value | $351 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $471,732 | OtherCostOrOtherBasisAmt |
| Depreciation | $409,331 | DepreciationAmt |
| Book Value | $62,401 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $86,511 | TotalBookValueLandBuildingsAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $15,333,499 | TotalRevEtcAuditedFinclStmtAmt |
| Revenue Not Reported | $0 | RevenueNotReportedAmt |
| Revenue Subtotal | $15,333,499 | RevenueSubtotalAmt |
| Revenue Not Reported Fincl Stmt | $0 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $15,333,499 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $14,665,939 | TotExpnsEtcAuditedFinclStmtAmt |
| Expenses Not Reported | $0 | ExpensesNotReportedAmt |
| Expenses Subtotal | $14,665,939 | ExpensesSubtotalAmt |
| Expenses Not Rpt Fincl Stmt | $0 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $14,665,939 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART X, LINE 2: | FormAndLineReferenceDesc |
| Explanation | FINANCIAL STATEMENT FIN 48 (ASC 740) FOOTNOTE: C-PATH IS EXEMPT FROM INCOME TAXES UNDER BOTH FEDERAL (INTERNAL REVENUE CODE SECTION 501(C)(3)) AND ARIZONA INCOME TAX LAWS, AND IS CLASSIFIED AS OTHER THAN A PRIVATE FOUNDATION. ACCORDINGLY, NO PROVISION FOR FEDERAL AND STATE INCOME TAXES IS MADE IN THE FINANCIAL STATEMENTS. INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO C-PATH'S TAX-EXEMPT PURPOSE, HOWEVER, MAY BE SUBJECT TO TAXATION AS UNRELATED BUSINESS TAXABLE INCOME (UBTI). GAAP REQUIRES MANAGEMENT TO PERFORM AN EVALUATION OF ALL TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN THE COURSE OF PREPARING C-PATH'S TAX RETURNS TO DETERMINE WHETHER THE TAX POSITIONS MEET A "MORE LIKELY THAN NOT" STANDARD OF BEING SUSTAINED UNDER EXAMINATION BY THE APPLICABLE TAXING AUTHORITIES. THIS EVALUATION IS REQUIRED TO BE PERFORMED FOR ALL OPEN TAX YEARS, AS DEFINED BY THE VARIOUS STATUTES OF LIMITATIONS, FOR FEDERAL AND STATE PURPOSES. C-PATH IS ONLY SUBJECT TO INCOME TAXES ON UBTI AS APPLICABLE. AS A RESULT, C-PATH IS REQUIRED TO FILE INFORMATIONAL RETURNS FOR FEDERAL AND STATE PURPOSES AND, IF IT HAS UBTI, FEDERAL AND STATE INCOME TAX RETURNS. MANAGEMENT HAS PERFORMED ITS EVALUATION OF TAX POSITIONS TAKEN ON ALL OPEN TAX RETURNS AND HAS DETERMINED THAT THERE WERE NO POSITIONS TAKEN THAT DO NOT MEET THE "MORE LIKELY THAN NOT" STANDARD. | ExplanationTxt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Region | EUROPE (INCLUDING ICELAND & GREENLAND) | RegionTxt |
| Offices | 0 | OfficesCnt |
| Employee | 0 | EmployeeCnt |
| Type Of Activities Conducted | GRANTS TO RECIPIENTS LOCATED IN REGION | TypeOfActivitiesConductedTxt |
| Specific Services Provided | CLINICAL RESEARCH | SpecificServicesProvidedTxt |
| Region Total Expenditures | $57,796 | RegionTotalExpendituresAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Continutation Total Office | 0 | ContinutationTotalOfficeCnt |
| Continutation Total Employee | 0 | ContinutationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Subtotal Spent | $57,796 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $57,796 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Region | EUROPE (INCLUDING ICELAND & GREENLAND) | RegionTxt |
| Purpose Of Grant | CLINICAL RESEARCH | PurposeOfGrantTxt |
| Cash Grant | $57,796 | CashGrantAmt |
| Manner Of Cash Disbursement | WIRE TRANSFER | MannerOfCashDisbursementTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 1 | Total501c3OrgCnt |
| Transfer To Foreign Corp | 0 | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | Yes (1) | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. | ExplanationTxt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (4 entries)
| Address Line1USAddress/AddressLine1Txt | Address Line2USAddress/AddressLine2Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Non Cash AssistanceNonCashAssistanceAmt | Purpose Of GrantPurposeOfGrantTxt |
|---|---|---|---|---|---|---|---|---|
| BAYLOR RESEARCH INSTITUTE | ||||||||
| 1950 N STEMMONS FREEWAY SUITE 5010 | LOCKBOX 846275 | DALLAS | TX | 75207 | 751921898 | 501(C)(3) | $1,287,756 | DEVELOP A HOLLOW FIBER MODEL FOR TUBERCULOSIS RESEARCH |
| UNIVERSITY OF CALIFORNIA | ||||||||
| 1855 FOLSOM STREET BOX 0897 | SAN FRANCISCO | CA | 94143 | 946036493 | STATE OF CALIFORNIA | $642,125 | DEVELOP A DISEASE PROGRESSION MODEL FOR TUBERCULOSIS | |
| UNIVERSITY OF FLORIDA | ||||||||
| PO BOX 113001 | GAINSVILLE | FL | 32611 | 596002052 | STATE OF FLORIDA | $162,040 | TO DEVELOP A POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODEL FOR TUBERCULOSIS. | |
| CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM | ||||||||
| PO BOX 2068 | ROUND ROCK | TX | 78680 | 043503931 | 501(C)(3) | $508,261 | DEVELOP CLINICAL DATA STANDARDS | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 4 | Total501c3OrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Form990 Of Other Organizations | Yes (X) | Form990OfOtherOrganizationsInd |
| Written Employment Contract | Yes (X) | WrittenEmploymentContractInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | 0 | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (8 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MARTHA A BRUMFIELD PHD | ||||||||||||||
| CHIEF EXECUTIVE OFFICER | $296,522 | $0 | $0 | $0 | $0 | $0 | $23,575 | $0 | $6,479 | $0 | $326,576 | $0 | $0 | $0 |
| STEVEN T BROADBENT MBA | ||||||||||||||
| CHIEF OPERATING OFFICER & TREASURER | $187,269 | $0 | $0 | $0 | $0 | $0 | $15,904 | $0 | $10,386 | $0 | $213,559 | $0 | $0 | $0 |
| ENRIQUE AVILES | ||||||||||||||
| SECRETARY | $157,130 | $0 | $0 | $0 | $0 | $0 | $11,871 | $0 | $10,384 | $0 | $179,385 | $0 | $0 | $0 |
| LYNN D HUDSON PHD | ||||||||||||||
| CHIEF SCIENCE OFFICER | $191,637 | $0 | $0 | $0 | $0 | $0 | $15,904 | $0 | $2,210 | $0 | $209,751 | $0 | $0 | $0 |
| JOHN-MICHAEL SAUER PHD | ||||||||||||||
| EXECUTIVE DIRECTOR PSTC | $179,842 | $0 | $0 | $0 | $0 | $0 | $14,565 | $0 | $11,973 | $0 | $206,380 | $0 | $0 | $0 |
| STEPHEN J COONS PHD | ||||||||||||||
| EXECUTIVE DIRECTOR PROC | $175,956 | $0 | $0 | $0 | $0 | $0 | $14,484 | $0 | $6,189 | $0 | $196,629 | $0 | $0 | $0 |
| DIANE STEPHENSON PHD | ||||||||||||||
| EXECUTIVE DIRECTOR CPP | $162,784 | $0 | $0 | $0 | $0 | $0 | $13,130 | $0 | $10,378 | $0 | $186,292 | $0 | $0 | $0 |
| DEBRA HANNA PHD | ||||||||||||||
| EXECUTIVE DIRECTOR CPTR | $159,054 | $0 | $0 | $0 | $0 | $0 | $13,169 | $0 | $9,422 | $0 | $181,645 | $0 | $0 | $0 |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (8 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS | THE CRITICAL PATH INSTITUTE (C-PATH) IS AN INDEPENDENT, NON-PROFIT ORGANIZATION UNIQUELY DEDICATED TO IMPLEMENTING THE FDA'S CRITICAL PATH INITIATIVE BY CREATING COLLABORATIONS AMONG REGULATORS (SCIENTISTS FROM THE FDA AND EMA) THE REGULATED (MEDICAL PRODUCT INDUSTRY), ACADEMIA, PATIENTS ORGANIZATIONS, AND OTHER ORGANIZATIONS THAT ADVANCE MEDICAL INNOVATION THROUGH THE DEVELOPMENT OF TOOLS AND METHODS BASED UPON SOUND, CONSENSUS BASED SCIENCE. THE ACCOMPLISHMENTS FOR THIS FISCAL YEAR REPORT INCLUDE: THE COALITION AGAINST MAJOR DISEASES DEVELOPS TOOLS AND PROCESSES TO ACCELERATE PROGRESS IN THE PREVENTION, TREATMENT AND CURE OF MAJOR NEURODEGENERATIVE DISEASES, INITIALLY FOCUSING ON ALZHEIMER'S AND PARKINSON'S DISEASES. THIS YEAR'S ACCOMPLISHMENTS INCLUDE: DEVELOPED AN INFORMED CONSENT FORM THAT WILL ENABLE BROADER SHARING OF PATIENT DATA AND SPECIMENS FOR FUTURE RESEARCH. OBTAINED REGULATORY ENDORSEMENT OF THE STATISTICAL ANALYSIS APPROACH FOR THE HIPPOCAMPAL VOLUME BIOMARKER QUALIFICATION EFFORT. RECEIVED THREE LETTERS OF SUPPORT FROM THE FDA ENCOURAGING THE FURTHER STUDY AND USE OF CEREBROSPINAL FLUID ANALYTES AB1-42, TOTAL-TAU, AND PHOSPHO-TAU, AND LOW BASELINE HIPPOCAMPAL VOLUME MEASURED BY MAGNETIC RESONANCE IMAGING AS EXPLORATORY PROGNOSTIC BIOMARKERS FOR ENRICHMENT IN TRIALS FOR AD; AND MOLECULAR NEUROIMAGING OF THE DOPAMINE TRANSPORTER AS AN EXPLORATORY PROGNOSTIC BIOMARKER FOR ENRICHMENT IN TRIALS FOR PARKINSON'S DISEASE. THE COALITION FOR ACCELERATING STANDARDS AND THERAPIES IS AN INITIATIVE TO ACCELERATE CLINICAL RESEARCH AND MEDICAL PRODUCT DEVELOPMENT BY CREATING AND MAINTAINING DATA STANDARDS, TOOLS, AND METHODS FOR CONDUCTING RESEARCH IN THERAPEUTIC AREAS THAT ARE IMPORTANT TO PUBLIC HEALTH. CFAST WAS INITIATED AS A PARTNERSHIP BETWEEN THE CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM (CDISC) AND THE CRITICAL PATH INSTITUTE (C-PATH). THE COALITION HAS DEVELOPED AND PUBLISHED THE FOLLOWING (22) CDISC THERAPEUTIC AREA STANDARDS: ALZHEIMER'S V1 AND 2, ASTHMA, BREAST CANCER, CARDIOVASCULAR, CHRONIC HEPATITIS C, DIABETES, DYSLIPIDEMIA, INFLUENZA, MULTIPLE SCLEROSIS, PAIN, PARKINSON'S DISEASE, POLYCYSTIC KIDNEY DISEASE, QT STUDIES, SCHIZOPHRENIA, TUBERCULOSIS V1 AND V2, VIROLOGY V1 AND V2, TRAUMATIC BRAIN INJURY, AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). A SEPARATE ANALYSIS DATA MODEL (ADAM) SUPPLEMENT WAS PUBLISHED FOR DIABETES. A NEW CONSORTIUM ENTITLED CRITICAL PATH FOR PARKINSON'S WAS LAUNCHED. ITS GOALS ARE TO DEVELOP QUANTITATIVE MODEL-BASED TOOLS TO ACCELERATE THE TREATMENT OF PARKINSON'S DISEASE, TARGETING PATIENTS AT THE FIRST CLINICAL SIGNS OF MOTOR SYMPTOM ONSET. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: RECEIVED SUPPORT FROM EMA TO PROCEED WITH QUALIFICATION PLAN FOR MOLECULAR NEUROIMAGING OF THE DOPAMINE TRANSPORTER AS A PROGNOSTIC BIOMARKER FOR ENRICHMENT IN TRIALS FOR EARLY PARKINSON'S DISEASE. RECEIVED A LETTER OF SUPPORT FROM THE EMA FOR THE USE OF DAT IMAGING AS AN ENRICHMENT BIOMARKER FOR PD CLINICAL TRIALS. THE MISSION OF THE CRITICAL PATH TO TB DRUG REGIMENS INITIATIVE IS TO ACCELERATE THE DEVELOPMENT OF NOVEL TB DRUG REGIMENS THAT ARE SAFER, SHORTER IN DURATION, AND MORE EFFICACIOUS THAN THE CURRENT STANDARD OF CARE. THEIR MISSION EXPANDED TO ALSO ACCELERATE THE DEVELOPMENT OF A CLINICALLY USEFUL IN VITRO RAPID DRUG SUSCEPTIBILITY ASSAY TO SUPPORT TB REGIMEN DEVELOPMENT AND DEPLOYMENT. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: THE EMA ISSUED A POSITIVE QUALIFICATION DECISION ON CPTR'S QUALIFIED IN VITRO HOLLOW FIBER SYSTEM MODEL FOR TUBERCULOSIS. THE WHO SELECTED C-PATH TO HOST TB CLINICAL TRIALS DATA PLATFORM. THE RESEQTB DATA PLATFORM LAUNCHED FOR USE BY RESEARCHERS, DATA CONTRIBUTORS AND CONSORTIA MEMBERS. TB-PLATFORM FOR AGGREGATION OF CLINICAL TB STUDIES LAUNCHED. DELIVERED A QUANTITATIVE MODEL FOR TIME-TO-POSITIVITY BEHAVIOR USING AN INTEGRATED DATABASE OF PHASE II STUDIES. MANUFACTURED NEW SENSITITRE PLATE CONTAINING CURRENT, NEW, AND REPURPOSED ANTI-TB DRUGS AND SHIPPED TO MULTIPLE SITES FOR ASSAY VALIDATION. COMPLETED 2 OF 7 MODELING AND SIMULATION TOOLS (PHARMACOLOGY BASED PHARMACOKINETICS AND QT INTERVAL MODELS). SUBMITTED COMMENTS TO FDA DRAFT GUIDANCE FOR INDUSTRY ON INFECTIOUS DISEASE NEXT GENERATION SEQUENCING BASED DIAGNOSTIC DEVICES: MICROBIAL IDENTIFICATION AND DETECTION OF ANTIMICROBIAL RESISTANCE AND VIRULENCE MARKERS. THE DATA COLLABORATION CENTER IS A NEWLY ESTABLISHED CENTER WITHIN C-PATH TO ENABLE MULTIPLE ORGANIZATIONS TO WORK TOGETHER IN A NEUTRAL SETTING AND SHARE CLINICAL DATA IN ORDER TO OPTIMIZE ITS VALUE IN CREATING NEW INSIGHTS AND TOOLS THAT ACCELERATE DRUG DEVELOPMENT IN AREAS WITH UNMET MEDICAL NEEDS. THE DCC SUPPORTS DATA SHARING PROJECTS ALIGNED WITH SPECIFIC C-PATH CONSORTIA AS WELL AS DATA SHARING INITIATIVES THAT ARE INDEPENDENT OF C-PATH CONSORTIA. ITS ACCOMPLISHMENTS THIS YEAR INCLUDE: PROVIDED DATA MANAGEMENT, CURATION, STANDARDIZATION, AND DATA SHARING SUPPORT FOR THE FOLLOWING C-PATH DATA PROJECTS: RELATIONAL SEQUENCING TB DATA PLATFORM, A DATA SHARING PLATFORM TO ADVANCE THE DEVELOPMENT OF TB RAPID DRUG SUSCEPTIBILITY TESTS; TB PLATFORM FOR AGGREGATION OF CLINICAL TRIAL STUDIES, A DATABASE TO AGGREGATE PHASE III TB CLINICAL TRIAL DATA SETS AND MAKE AVAILABLE TO RESEARCHERS FOR THE WORLD HEALTH ORGANIZATION; TB-ALLIANCE, AN AGGREGATED COLLECTION OF TB CLINICAL TRIAL DATA SETS THAT THE TB-ALLIANCE ORGANIZATION IS MAKING AVAILABLE TO QUALIFIED RESEARCHERS; SIX OF C-PATH'S CONSORTIA WITH DATABASE REQUIREMENTS. THE DCC ALSO COMPLETED ITS BUSINESS PLAN. A NEW CONSORTIUM ENTITLED DUCHENNE REGULATORY SCIENCE CONSORTIUM WAS LAUNCHED. ITS GOAL IS TO SUPPORT COLLABORATIVE RESEARCH AND REGULATORY QUALIFICATION OF NEW DRUG DEVELOPMENT TOOLS FOR DUCHENNE MUSCULAR DYSTROPHY, TO ENABLE THE EARLIEST POSSIBLE PATIENT ACCESS TO NEW TREATMENTS. SPECIFIC GOALS INCLUDE DEVELOPING A CLINICAL DATA SHARING PLATFORM, A CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM (CDISC) THERAPEUTIC AREA STANDARD, AND A DISEASE PROGRESSION MODEL FOR DUCHENNE. ACCOMPLISHMENTS THIS YEAR INCLUDE: HELD FIRST EXPERT MEETING IN NOVEMBER 2015 TO DISCUSS THE ELEMENTS NEEDED TO BE INCLUDED IN THE MODEL AND TO PRIORITIZE DATASETS. DEVELOPED AN INITIAL WORK PLAN FOR THE PROGRESSION MODEL, FOR FURTHER DISCUSSION WITH THE REGULATORY AUTHORITIES AND TO FOCUS DATA COLLECTION. ACQUIRED FOUR DATASETS AND DATA SHARING AGREEMENTS FOR ADDITIONAL DATASETS ARE UNDERWAY. THE GOAL OF THE ELECTRONIC PATIENT REPORTED OUTCOME CONSORTIUM IS TO ADVANCE THE SCIENCE OF CLINICAL TRIAL ENDPOINT ASSESSMENT BY COLLABORATIVELY SUPPORTING AND CONDUCTING RESEARCH, DESIGNING AND DELIVERING EDUCATIONAL OPPORTUNITIES, AND DEVELOPING AND DISSEMINATING BEST PRACTICE RECOMMENDATIONS FOR ELECTRONIC COLLECTION OF CLINICAL OUTCOME DATA. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: PARTICIPATED IN GCP INSPECTORS WORKING GROUP AND INTERESTED PARTIES JOINT MEETING AT THE EMA AND PRESENTED THE CONSORTIUM'S POSITION ON SOURCE DATA AND BYOD. COLLABORATED IN THE DEVELOPMENT OF A STUDY DESIGN TO SUPPORT A PROJECT TITLED "COMPARABILITY OF PROVISIONED DEVICE VS BRING-YOUR-OWN-DEVICE IN SUBJECTS WITH COPD." SEVEN NEW PRO INSTRUMENTS HAVE BEEN IMPLEMENTED ELECTRONICALLY. LAUNCHED A STUDY TO PROVIDE EMPIRICAL EVIDENCE TO SUPPORT THE MEASUREMENT EQUIVALENCE OF DATA COLLECTED ON VARIOUS DATA COLLECTION MODES (I.E., PAPER, HANDHELD, TABLET, INTERACTIVE VOICE RESPONSE [IVR], AND WEB). THE QUALITATIVE COMPONENT OF THE STUDY HAS BEEN COMPLETED AND THE QUANTITATIVE PORTION IS UNDERWAY. THE MULTIPLE SCLEROSIS OUTCOME ASSESSMENT CONSORTIUM HAS A GOAL TO OBTAIN REGULATORY QUALIFICATION OF AN IMPROVED CLINICAL OUTCOME ASSESSMENT INSTRUMENT AS A PRIMARY ENDPOINT IN CLINICAL TRIALS OF MULTIPLE SCLEROSIS (MS) THERAPIES. THEIR ACCOMPLISHMENTS INCLUDE: DEVELOPED A CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM (CDISC) THERAPEUTIC AREA USER GUIDE FOR MS. ACQUIRED THE CONTROL AND TREATMENT ARMS OF 16 CLINICAL TRIAL DATASETS (14,430 PATIENT RECORDS), CURATED THE DATA, AND REMAPPED AND POOLED MOST OF THE DATA TO THE CDISC STUDY DATA TABULATION MODEL (SDTM) STANDARD. RECEIVED FEEDBACK ON THE INITIAL BRIEFING PACKAGE FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) AND EUROPEAN MEDICINES AGENCY (EMA). COMPLETED AN EXTENSIVE LITERATURE REVIEW. THE STATISTICS ANALYSIS PLAN WAS FINALIZED AND EXECUTED FOR THE FDA SUBMISSION. ESTABLISHED THE MSOAC PLACEBO DATABASE FOR USE IN APPROVED MS RESEARCH. WORK IS PROCEEDING ON SINGLE DOMAIN OF DISABILITY FOR THE FDA (I.E., COGNITION), WHILE MAINTAINING THE ORIGINAL FOCUS FOR THE EMA. |
| FORM 990, PART III, LINE 4A | THE GOAL OF THE INTERNATIONAL NEONATAL CONSORTIUM IS TO ACCELERATE THE DEVELOPMENT OF SAFE AND EFFECTIVE THERAPIES FOR NEONATES. IT ENGAGES THE GLOBAL NEONATAL COMMUNITY - FAMILIES, NEONATAL NURSES, ACADEMIC SCIENTISTS, REGULATORS, PHARMACEUTICAL INVESTIGATORS, ADVOCACY ORGANIZATIONS, AND FUNDERS - TO FOCUS ON THE NEEDS OF THE NEONATE. THROUGH TEAMS THAT SHARE DATA, KNOWLEDGE, AND EXPERTISE, THE CONSORTIUM WILL DEVELOP TOOLS THAT CAN BE INCORPORATED INTO CLINICAL TRIALS FOR NEONATES. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: HELD A FACE-TO-FACE WORKSHOP IN WASHINGTON, DC, ON TO DRAFT A WHITE PAPER REGARDING CONSENSUS-BASED CRITICAL ELEMENTS OF CLINICAL PHARMACOLOGY STUDIES IN NEONATES WHICH COULD BE CONSIDERED BY REGULATORS IN PREPARATION OF FUTURE GUIDANCE DOCUMENTS, INCLUDING RECOMMENDATIONS FOR SAFER FORMULATIONS ENCOMPASSING EASE OF ADMINISTRATION. SUBMITTED COMMENTS ON THE NOTICE OF PROPOSED RULEMAKING (NPRM) "FEDERAL POLICY FOR THE PROTECTION OF HUMAN SUBJECTS" TO THE OFFICE FOR HUMAN RESEARCH PROTECTIONS AND SUPPLIED INPUT ON DRUGS AND THERAPEUTIC AREAS THAT REQUIRE FURTHER STUDY IN NEONATES IN RESPONSE TO NICHD'S REQUEST FOR INFORMATION ON THE BEST PHARMACEUTICALS FOR CHILDREN ACT PRIORITIES IN PEDIATRIC THERAPEUTICS 2017. THE GOAL OF THE POLYCYSTIC KIDNEY DISEASE OUTCOMES CONSORTIUM IS TO DEVELOP AND OBTAIN REGULATORY QUALIFICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) AND THE EUROPEAN MEDICINES AGENCY (EMA) OF TOTAL KIDNEY VOLUME (TKV) AS A PROGNOSTIC BIOMARKER FOR USE IN CLINICAL TRIALS FOR NEW THERAPIES FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD). AFTER SUCCESSFULLY ACCOMPLISHING THE PRIMARY GOAL, THE CONSORTIUM IS NOW WORKING ON OTHER REGULATORY CHALLENGES, CLINICAL TRIAL DESIGNS, EXPLORATORY ENDPOINTS, AND THE POSSIBILITY OF QUALIFYING TKV AS A SURROGATE ENDPOINT. THEIR ACCOMPLISHMENTS FOR THIS YEAR INCLUDE: RECEIVED A LETTER OF SUPPORT FROM THE FDA FOR THE EXPLORATORY USE OF TKV IN CLINICAL TRIALS FOR ADPKD. RECEIVED A FORMAL QUALIFICATION OF TKV AS A PROGNOSTIC BIOMARKER FROM THE FDA IN THE FORM OF A DRAFT GUIDANCE (AUGUST, 2015) AND FROM THE EMA AS A QUALIFICATION OPINION (NOVEMBER, 2015). HELD A VERY SUCCESSFUL ADPKD SUMMIT MEETING WITH INDUSTRY, ACADEMIA, AND INTERNATIONAL REGULATORS TO DISCUSS POTENTIAL SOLUTIONS TO ADDRESS THE NEED FOR BETTER CLINICAL ENDPOINTS FOR CLINICAL TRIALS OF NEW THERAPIES FOR ADPKD. FORMAL QUALIFICATION OF TKV AS A PROGNOSTIC BIOMARKER WAS RECEIVED FROM THE FDA IN THE FORM OF FINAL GUIDANCE ON SEPTEMBER 15TH, 2016. TKV WAS ACCEPTED AS A "REASONABLY LIKELY SURROGATE" BY THE FDA ALLOWING IT TO BE USED IN ACCELERATED APPROVAL APPLICATIONS. THE GOAL OF THE PATIENT-REPORTED OUTCOME CONSORTIUM IS TO ESTABLISH AND MAINTAIN A COLLABORATIVE FRAMEWORK WITH APPROPRIATE STAKEHOLDERS FOR THE QUALIFICATION OF PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS AND OTHER CLINICAL OUTCOME ASSESSMENT (COA) TOOLS THAT WILL BE PUBLICLY AVAILABLE FOR USE IN CLINICAL TRIALS WHERE COA-BASED ENDPOINTS ARE USED TO SUPPORT PRODUCT LABELING CLAIMS. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: THE FOLLOWING PRO INSTRUMENTS ARE IN VARIOUS STAGES OF THE QUALIFICATION PROCESS: FOR THE ASTHMA DAILY SYMPTOM DIARY, A QUANTITATIVE PILOT STUDY WAS COMPLETED AND QUANTITATIVE PILOT STUDY REPORT AND QUANTITATIVE DATA SUBMITTED TO FDA QRT FOR REVIEW. FOR THE SYMPTOMS OF MAJOR DEPRESSIVE DISORDER SCALE, A QUANTITATIVE PILOT STUDY WAS COMPLETED AND QUANTITATIVE PILOT STUDY REPORT AND QUANTITATIVE DATA WAS SUBMITTED TO FDA FOR REVIEW. FOR THE FUNCTIONAL DYSPEPSIA SYMPTOM DIARY, THE QUALITATIVE RESEARCH WAS COMPLETED AND QUALITATIVE RESEARCH SUMMARY REPORT IS IN DEVELOPMENT. FOR THE THREE INSTRUMENTS FOR IRRITABLE BOWEL SYNDROME, THE QUANTITATIVE PILOT STUDY PROTOCOL AND ANALYSIS PLAN WAS REVIEWED BY FDA, THEIR SUGGESTIONS WERE INCORPORATED INTO THE STUDY DOCUMENTS, AND A QUANTITATIVE PILOT STUDY IS BEING LAUNCHED. FOR THE NON-SMALL CELL LUNG CANCER SYMPTOM ASSESSMENT QUESTIONNAIRE, THE QUANTITATIVE PILOT STUDY WAS COMPLETED AND THE QUANTITATIVE PILOT STUDY REPORT IS IN DEVELOPMENT. THE PREDICTIVE SAFETY TESTING CONSORTIUM BRINGS TOGETHER PHARMACEUTICAL COMPANIES TO SHARE AND VALIDATE INNOVATIVE SAFETY TESTING METHODS UNDER ADVISEMENT OF THE U.S. FOOD AND DRUG ADMINISTRATION, EUROPEAN MEDICINES AGENCY, AND JAPAN'S PHARMACEUTICALS AND MEDICAL DEVICES AGENCY. CURRENTLY THE PSTC IS FOCUSED ON DEVELOPING AND OBTAINING REGULATORY QUALIFICATION OF IMPROVED CLINICAL SAFETY BIOMARKERS FOR USE IN DRUG DEVELOPMENT. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: RECEIVED EMA AND FDA LETTERS OF SUPPORT FOR FOUR SKELETAL MUSCLE INJURY BIOMARKERS IN RODENTS. SUBMITTED LIMITED CONTEXT OF USE QUALIFICATION PACKAGE TO FDA AND EMA OF A COMPOSITE MEASURE OF KIDNEY SAFETY BIOMARKERS FOR USE IN CLINICAL DRUG DEVELOPMENT STUDIES. SUBMITTED LETTER OF INTENT FOR THE QUALIFICATION OF GLUTAMATE DEHYDROGENASE AS A SPECIFIC BIOMARKER OF DRUG-INDUCED HEPATIC INJURY IN HUMANS. SUBMITTED PACKAGES FOR DILI, DIKI, AND DIVI BIOMARKERS TO EMA AND FDA FOR REVIEW WITH THE INTENT OF RECEIVING LETTERS OF SUPPORT. RECEIVED FDA LETTERS OF SUPPORT FOR LIVER SAFETY BIOMARKERS FOR USE IN CLINICAL DRUG DEVELOPMENT. A NEW CONSORTIUM ENTITLED PEDIATRICS TRIAL CONSORTIUM WAS LAUNCHED THIS YEAR. THE GOAL IS TO PROVIDE THE SUPPORT AND GUIDANCE NECESSARY FOR THE CRITICAL PATH INSTITUTE (C-PATH) TO CREATE A NEW NON-PROFIT ORGANIZATION THAT WILL WORK INDEPENDENTLY (BUT WITH INPUT FROM RELEVANT SECTORS) TO ADDRESS THE GAPS IN PEDIATRIC CLINICAL DEVELOPMENT. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: LAUNCHED A NEW INDEPENDENT ORGANIZATION CALLED INSTITUTE FOR ADVANCED CLINICAL TRIALS FOR CHILDREN. APPLIED FOR A 501(C)(3) NON-PROFIT STATUS THAT IS PENDING. INITIAL DIRECTORS AND OFFICERS HAVE BEEN APPOINTED AND BYLAWS HAVE BEEN ADOPTED. DEVELOPED AN OPERATIONAL PLAN ADDRESSING: GLOBAL INTEROPERABILITY WITH OTHER INITIATIVES; RECOMMENDATIONS ON LEADERSHIP ROLES; FUNDING STRATEGY. WROTE AND HAD EXTENSIVE LEGAL REVIEW ON AN ADVISORY REPORT. |
| FORM 990, PART VI, SECTION A, LINE 2 | LYLE BOOTMAN AND SHAUN KIRKPATRICK HAVE A BUSINESS RELATIONSHIP. MIKE KASSER AND JEFF JACOB HAVE A BUSINESS RELATIONSHIP. ALAN LEVIN AND PETER CORR HAVE A BUSINESS RELATIONSHIP. |
| FORM 990, PART VI, SECTION B, LINE 11 | FORM 990 IS PREPARED BY AN EXTERNAL CPA FIRM USING INFORMATION PROVIDED BY THE ORGANIZATION. THE FORM IS REVIEWED BY THE ORGANIZATION'S COMPTROLLER, COO, PRESIDENT/CEO, AN OUTSIDE CPA, THE BOARD AUDIT, FINANCE, AND RISK COMMITTEE, AND THE BOARD OF DIRECTORS PRIOR TO BEING FINALIZED. |
| FORM 990, PART VI, SECTION B, LINE 12C | ALL MEMBERS OF THE BOARD OF DIRECTORS AND ALL OFFICERS OF THE ORGANIZATION ARE REQUIRED TO FILL OUT A CONFLICT OF INTEREST FORM ANNUALLY. THE RESULTS ARE COMPILED AND REVIEWED BY THE BOARD'S AUDIT, FINANCE, AND RISK COMMITTEE. ANY ACTUAL OR PERCEIVED CONFLICTS THAT HAVE THE POTENTIAL TO BIAS ANY DISCUSSIONS OR DECISIONS BY THE BOARD ARE DISCUSSED BY THE BOARD. ANY DIRECTOR WITH A REAL OR POTENTIAL CONFLICT WILL RECUSE THEMSELVES FROM ANY DISCUSSION OR DECISION WHERE THE CONFLICT HAS A BEARING. |
| FORM 990, PART VI, SECTION B, LINE 15 | A BOARD OF DIRECTORS COMPENSATION COMMITTEE MEETS AND REVIEWS EXECUTIVE COMPENSATION ANNUALLY. EVERY FEW YEARS THE COMMITTEE SEEKS AN INDEPENDENT COMPENSATION CONSULTING ORGANIZATION. AFTER THE CONSULTING ORGANIZATION HAS BEEN RETAINED, THE COMPENSATION COMMITTEE RECEIVES THE CONSULTANT'S EXECUTIVE COMPENSATION REVIEWS AND RECOMMENDATIONS. THIS INFORMATION IS THEN USED AS A BASIS FOR THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF DIRECTORS. THE LAST INDEPENDENT COMPENSATION SURVEY WAS CONDUCTED FOR THE CEO IN AUGUST 2011. THE CEO'S SALARY HAS REMAINED CONSTANT SINCE THE TIME OF HER HIRE. AN OVERALL SALARY PROGRAM FOR EMPLOYEES MUST BE APPROVED BY THE BOARD OF DIRECTORS COMPENSATION COMMITTEE BEFORE IMPLEMENTATION. ALL EMPLOYEE SALARY INCREASES MUST BE APPROVED BY THE PRESIDENT/CEO. |
| FORM 990, PART VI, SECTION C, LINE 19 | ARTICLES OF INCORPORATION CAN BE FOUND ON THE ARIZONA CORPORATION COMMISSION WEBSITE. THE CONFLICT OF INTEREST POLICY AND THE FINANCIAL STATEMENTS (VIA THE ANNUAL REPORT) ARE POSTED ON THE INSTITUTE'S WEBSITE. |
| FORM 990, PART IX, LINE 11G | RESEARCH SUPPORT SERVICES: PROGRAM SERVICE EXPENSES 1,405,309. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,405,309. CONSULTING: PROGRAM SERVICE EXPENSES 1,027,701. MANAGEMENT AND GENERAL EXPENSES 37,144. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,064,845. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 924,300. MANAGEMENT AND GENERAL EXPENSES 13,390. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 937,690. |
Schedule R IRS990ScheduleR
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (2 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Exempt Code SectionExemptCodeSectionTxt | Public Charity StatusPublicCharityStatusTxt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt | Controlled OrganizationControlledOrganizationInd | Address Line1ForeignAddress/AddressLine1Txt | CityForeignAddress/CityNm | CountryForeignAddress/CountryCd | Foreign PostalForeignAddress/ForeignPostalCd | Legal Domicile Foreign CountryLegalDomicileForeignCountryCd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| THE CRITICAL PATH FOUNDATION | |||||||||||||||
| 1730 EAST RIVER ROAD SUITE 200 | TUCSON | AZ | 85718 | 204780896 | RAISING AND CONTRIBUTING FUNDS TO CRITICAL PATH INSTITUTE | AZ | 501(C)(3) | 11 | CRITICAL PATH INSTITUTE | Yes (1) | |||||
| CRITICAL PATH GLOBAL LTD | |||||||||||||||
| FACILITATE WORK WITH EUROPEAN MEDICINES AGENCY | CRITICAL PATH INSTITUTE | Yes (1) | 20-22 BEDFORD ROW | LONDON | UK | WC1R 4JS | UK | ||||||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | 0 | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | 0 | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | 0 | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | 0 | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | 0 | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | 0 | DivRelatedOrganizationInd |
| Asset Sale To Other Org | 0 | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | 0 | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | 0 | AssetExchangeInd |
| Rental Of Facilities To Oth Org | 0 | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | 0 | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | 0 | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | 0 | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | Yes (1) | SharingOfFacilitiesInd |
| Paid Employees Sharing | Yes (1) | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | 0 | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | 0 | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | 0 | TransferToOtherOrgInd |
| Transfer From Other Org | 0 | TransferFromOtherOrgInd |